|Bid||133.18 x 300|
|Ask||133.29 x 100|
|Day's Range||132.88 - 136.95|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-236.92|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Eli Lilly & Co. reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, ...
Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
Despite rampant rumors, Gilead is not likely to acquire either Incyte or Vertex. Here's why.